Sympathetic Mechanisms in Obesity-Crossover Design
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.
Sponsor: Vanderbilt University Medical Center
You may qualify if…
- ✓ Males and females of all races between 18 and 65 years of age
- ✓ Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication.
- ✓ Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2.
- ✓ Able and willing to provide informed consent.
You may not qualify if…
- ✕ Pregnancy or breast feeding
- ✕ Current smokers or history of heavy smoking (\>2 packs/day)
- ✕ History of alcohol or drug abuse
- ✕ Previous allergic reaction to study medications
- ✕ Type I diabetes.
- ✕ Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
- ✕ History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
- ✕ History or presence of immunological or hematological disorders
Where it's recruiting
Nashville
Source: ClinicalTrials.gov · NCT05312892 · last updated 2026-02-27